Grace Lytle OD, MS Joins Avellino Labs As Senior Medical Director

MENLO PARK, Calif., Nov. 16, 2015 /PRNewswire/ -- Avellino Lab USA, developer of the first genetic test for corneal dystrophy, today announced that Grace Lytle OD, MS has joined the company as Senior Medical Director. Currently focused on commercialization, the company has tested more than 500,000 patients for inherited corneal dystrophy with its DNA safety test to date and protected over 500 positive patients from complications and loss of vision.

Avellino Lab USA.
"Grace has played a pivotal role in leading clinical studies and coordinating physician education to establish new ophthalmic technology and clinical practices among US and international cornea specialists.  This experience directly correlates with the challenge in front of Avellino Labs.  Grace will play a key role in our efforts to focus on evidence based education in building a foundation for our global business," commented Peter Falzon, CEO of Avellino Lab USA.

Grace distinguished herself at the New England College of Optometry by graduating first in her doctoral class, and continued on with post-graduate research and numerous publications. After completing advanced residency training in cornea and contact lens at the New England Eye Institute, Grace worked as an optometrist in clinical practice for several years before entering industry as a director and vice president of professional education.

About Avellino Lab USA
Avellino Lab is currently the industry leader in LASIK and refractive surgery safety testing, offering the first and only commercially available test for corneal dystrophy. Refractive surgery is known to exacerbate corneal dystrophy, causing vision loss and blindness in refractive surgery patients whose corneal dystrophy may not be detectable without the Avellino DNA Test. By screening for corneal dystrophy prior to refractive surgery, patients who test negative for the mutations can move forward with the surgery with confidence. The current test was first introduced to the U.S. market in April 2014 and is now available in 50 countries.

To learn more please visit

Media Contact:
Scott Korney, COO
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.